Surzetoclax (ABBV-453)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
Arms / Cohorts
Experimental:Substudy 1: Dose Expansion and Selection ABBV-453 Combination
Accepting patients
Experimental:Substudy 2: Dose Escalation ABBV-453 Monotherapy
Accepting patients
Active Comparator:Substudy 1: Dose Expansion and Selection Control
Accepting patients
Experimental:Substudy 1: Dose Escalation ABBV-453 Combination
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.